STOCK TITAN

Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company, will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 1:30 p.m. PT in San Francisco. CEO John Houston will lead the presentation, focusing on the company's innovative approach to targeted protein degradation. Arvinas utilizes its proprietary PROTAC® Discovery Engine to develop therapies aimed at devastating diseases, including investigational programs for metastatic prostate and breast cancer. A live audio webcast of the presentation will be available online.

Positive
  • None.
Negative
  • None.

NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT in San Francisco, Calif.

A live audio webcast of the presentation will be available here and on the Events & Presentations section of the Investors & Media section of the Company’s website.

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com


FAQ

When will Arvinas present at the J.P. Morgan Healthcare Conference?

Arvinas will present on January 11, 2023, at 1:30 p.m. PT.

Who will represent Arvinas at the conference?

John Houston, Ph.D., President and CEO of Arvinas, will present.

What is the focus of Arvinas' presentation?

The presentation will cover Arvinas' targeted protein degradation approach and its clinical-stage programs.

Where can I watch the Arvinas presentation live?

The live audio webcast can be accessed on Arvinas' website and through the provided link.

What are the clinical-stage programs of Arvinas?

Their programs include bavdegalutamide (ARV-110), ARV-766 for prostate cancer, and ARV-471 for breast cancer.

Arvinas, Inc

NASDAQ:ARVN

ARVN Rankings

ARVN Latest News

ARVN Stock Data

1.22B
62.43M
7.22%
109.24%
12.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN